BIM
JNCE

Bogle Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bogle Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,842
Closed -$40K – 411
2018
Q4 		$40K Sell
11,842
-18,346
-61% -$85.7K ﹤0.01% 319
2018
Q3 		$196K Buy
+30,188
New +$224K 0.01% 257

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bogle Investment Management's JNCE Position: Q1 2019 in Review

Bogle Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 11,842 shares — an estimated $40K sold.

Bogle Investment Management first reported a position in JNCE in Q3 2018 and held it in 2 quarters. The position peaked at $196K in Q3 2018. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Bogle Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Bogle Investment Management sold 11,842 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $40K.
  • Bogle Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Bogle Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $196K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Bogle Investment Management's 13F filing for Q1 2019, filed 13 May 2019.